Fig. 7: Innate immune response in C57BL/6 mice vaccinated with rNA-N1-MPP vaccine adjuvanted with BDX100 or BDX301 after the challenge with A/bald eagle/Florida/W22-134-OP/2022 (H5N1) influenza virus. | npj Vaccines

Fig. 7: Innate immune response in C57BL/6 mice vaccinated with rNA-N1-MPP vaccine adjuvanted with BDX100 or BDX301 after the challenge with A/bald eagle/Florida/W22-134-OP/2022 (H5N1) influenza virus.

From: Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants

Fig. 7

a Percentage of different innate immune cell populations in mouse lungs 5 days after the challenge with 0.1 × LD50 (2 × 102 PFU/mouse) of A/bald eagle/Florida/W22-134-OP/2022 (H5N1 reassortant with A/Puerto Rico/8/1934 vaccine backbone) influenza virus (mean ± SE). b Viral titers in lungs on day 5 after the challenge with 0.1 × LD50 (2 × 102 PFU/mouse) of A/bald eagle/Florida/W22-134-OP/2022 H5N1 (n = 5). c Cytokine concentrations in BALFs on day 5 after the challenge (mean ± SE). Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots. d Principal component analysis (PCA) biplot represents the distribution of mice in accordance with the parameters of the immune response as well as factor loads of analyzed variables on the first two principal components. Variables for the PCA were selected based on the results of group comparison using ANOVA.

Back to article page